The Food and Drug Administration approves a new Pfizer drug to treat a rare, fast-progressing form of leukemia. The agency also expands the use Lynparza, sold by AstraZeneca and Merck & Co, to treat recurrent ovarian cancer. In other pharmaceutical news, changes to 340B program are delayed and a biopharma executive encounters challenges when trying to fund his own project.
- Viewpoints: Living Free But Addicted To Opioids; The Challenges Women In Medicine Face
- HIV Shouldn’t Be a Death Sentence. In Venezuela, Thousands Are Dying
- For $39 A Month, This ‘Woebot’ May Fill Gaps For Patients Who Can’t See A Therapist
- FDA Issues New Approvals For Leukemia, Ovarian Cancer Medicines
- Charlottesville Postmortem: Why People Join Hate Groups